Evidence map›Paper›PMID 27805066›Full record

ArticleScientific reports2016

Large-scale identification of adverse drug reaction-related proteins through a random walk model.

Xiaowen Chen, Hongbo Shi, Feng Yang, Lei Yang, Yingli Lv, Shuyuan Wang, Enyu Dai, Dianjun Sun, Wei Jiang

Abstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaowen ChenCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Hongbo ShiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Feng YangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Lei YangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Yingli LvCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Shuyuan WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Enyu DaiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.
Dianjun SunCenter for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, 150081, China.
Wei JiangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adverse drug reactions (ADRs) are responsible for drug failure in clinical trials and affect life quality of patients. The identification of ADRs during the early phases of drug development is an important task. Therefore, predicting potential protein targets eliciting ADRs is essential for understanding the pathogenesis of ADRs. In this study, we proposed a computational algorithm,Integrated Network for Protein-ADR relations (INPADR), to infer potential protein-ADR relations based on an integrated network. First, the integrated network was constructed by connecting the protein-protein interaction network and the ADR similarity network using known protein-ADR relations. Then, candidate protein-ADR relations were further prioritized by performing a random walk with restart on this integrated network. Leave-one-out cross validation was used to evaluate the ability of the INPADR. An AUC of 0.8486 was obtained, which was a significant improvement compared to previous methods. We also applied the INPADR to two ADRs to evaluate its accuracy. The results suggested that the INPADR is capable of finding novel protein-ADR relations. This study provides new insight to our understanding of ADRs. The predicted ADR-related proteins will provide a reference for preclinical safety pharmacology studies and facilitate the identification of ADRs during the early phases of drug development.

Indexed as

AlgorithmsArea Under CurveComputational BiologyDatabases, PharmaceuticalDatabases, ProteinDrug-Related Side Effects and Adverse ReactionsGene Regulatory NetworksHumansProtein Interaction MappingProtein Interaction MapsProteinsProteins

Identifiers

PMID27805066
PMCPMC5090865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.